Have your parents or grandparents ever had trouble driving, reading or recognizing faces? They might be suffering from ...

It is caused by abnormal blood vessel growth (a condition referred to as 'wet' macular degeneration) or atrophy and accumulation of debris ('dry' macular degeneration), both of which damage the ...

The following is a summary of “Phase 1 Study of JNJ-81201887 Gene Therapy in Geographic Atrophy Secondary to Age-Related ...

Prevent Blindness announces its fourth annual Geographic Atrophy Awareness Week, December 2 to 8, 2024. The organization ...

Outlook Therapeutics' Lytenava has become the first ophthalmic formulation of VEGF inhibitor bevacizumab to be cleared for use by the NHS in England and Wales for treating wet age-related m ...

Geographic atrophy (GA) is the advanced stage of age-related macular degeneration. While certain factors, like age and genetics, can increase your risk, others, like not smoking, may help slow or ...

Based on the scientific progress achieved in the past few years, it is possible that patients with myopic macular degeneration complicated by CNV may benefit from a new ophthalmic frontier of ...

A new study has linked moderate-to-severe obstructive sleep apnea (OSA), characterized by low oxygen levels overnight, with an increased risk of developing wet age-related macular degeneration (AMD).

Purpose To prospectively analyse microperimetry, standard short-wavelength fundus autofluorescent (SW-FAF) and near infrared-wavelength FAF (NIR-FAF) changes in eyes with geographic atrophy (GA) ...

Photodynamic therapy with verteporfin of CNV represents an advancement in the treatment of myopic macular degeneration complicated ... of chorioretinal atrophy. Limited macular translocation ...

Risuteganib is under clinical development by Allegro Ophthalmics and currently in Phase II for Dry (Atrophic) Macular Degeneration. According to... Likelihood of Approval and Phase Transition Success ...